

Lonsurf® (trifluridine/tipiracil) - New indication

- On Februarys 25, 2019, <u>Taiho Oncology announced</u> the FDA approval of <u>Lonsurf</u> (<u>trifluridine/tipiracil</u>), for the treatment of adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or <u>irinotecan</u>, and if appropriate, HER2/neutargeted therapy.
- Lonsurf is also approved for the treatment of adult patients with metastatic colorectal cancer
 previously treated with fluoropyrimidine-, <u>oxaliplatin-</u> and irinotecan-based chemotherapy, an antiVEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
- Gastric cancer is the fifteenth most commonly diagnosed cancer in the U.S. In 2018, there were an
 estimated 26,240 new cases and 10,800 deaths in the U.S. Approximately 35% of U.S. patients with
 gastric cancer are diagnosed at the distant or metastasized stage and metastatic gastric cancer is
 associated with a five-year survival rate of about 5%.
- The approval of Lonsurf's new indication was based on TAGS, a double-blind study in 507 patients
 with metastatic gastric or GEJ adenocarcinoma previously treated with at least 2 prior regimens for
 advanced disease. Patients were randomized to receive Lonsurf or placebo until disease
 progression or unacceptable toxicity. The major efficacy outcome measure was overall survival (OS)
 and an additional outcome measure was progression-free survival (PFS).
 - Median OS was 5.7 months (95% CI: 4.8, 6.2) for Lonsurf vs. 3.6 months (95% CI: 3.1, 4.1) for placebo (Hazard Ratio [HR]: 0.69; 95% CI: 0.56, 0.85; p = 0.0006).
 - There was also a statistically significant improvement in PFS with Lonsurf vs. placebo (HR: 0.56; 95% CI: 0.46, 0.68; p < 0.0001).
- The recommended dosage of Lonsurf for both indications is 35 mg/m² up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on days 1 through 5 and days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity.
 - The dose should be rounded to the nearest 5 mg increment.
 - Refer to the Lonsurf drug label for additional dosing recommendations.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.